GLP-1 Receptor Agonists: Clinical Evidence & Safety
GLP-1 receptor agonists safety profile is critical for clinicians prescribing these agents for weight loss and metabolic health. Clinical evidence shows meaningful benefits alongside manageable side effects. Understanding safety helps optimize patient…
Tirzepatide Dual GIP/GLP-1 Agonism: Clinical Evidence & Safety
Tirzepatide dual GIP GLP-1 agonism clinical evidence shows superior weight loss and glycemic control compared to semaglutide. This dual mechanism offers enhanced efficacy for type 2 diabetes and obesity management. Safety profiles remain comparable, with…
Tirzepatide vs Semaglutide: Clinical Evidence Comparison
This article reviews clinical evidence comparing tirzepatide versus semaglutide, focusing on weight loss and glycemic control. Tirzepatide's dual receptor agonism offers distinct advantages over semaglutide's GLP-1 only action. Understanding these…
GLP-1 Drugs for Obesity: EU Reimbursement Guide
GLP-1 reimbursement Europe policies are transforming obesity treatment access across the EU. This guide covers coverage for drugs like semaglutide and tirzepatide. Understanding reimbursement helps clinicians support patient adherence and outcomes.
Policy Watch: 20 Regulatory Updates — June 02, 2026
The schedules of controlled substances placement June 02 2026 report covers 20 regulatory updates affecting synthetic cannabinoids and opioids. These placements impact clinical research and patient care. Clinicians should stay informed on these…
Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
The DEA has designated synthetic cannabinoids schedule I designation for CUMYL-PEGACLONE due to its high abuse potential and no accepted medical use. This scheduling reflects ongoing regulatory efforts to control novel synthetic cannabinoids. Clinicians…
Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
The DEA has placed diphenidine in Schedule I, classifying it as a controlled substance with high abuse potential. Diphenidine is a synthetic dissociative drug posing public health risks. Awareness of diphenidine schedule I status aids clinicians in…
Ancient Cannabis Use: Evidence from Early Civilizations and Medicine
When patients ask about ancient cannabis use, the historical evidence proves surprisingly compelling. Early civilizations documented medicinal cannabinoid applications across multiple cultures and time periods. Understanding this historical context helps…
Why Cannabis Tolerance Feels Like Chasing a Running Away Balloon
Cannabis tolerance develops when your cannabinoid receptors adapt to regular use, creating a chase for dopamine regulation that feels like pursuing a drifting balloon. This process involves complex neurochemical changes that affect how your brain…
Why Consistent Cannabis Dosing Matters for Your Endocannabinoid System
Your endocannabinoid system functions best when cannabis dosing remains consistent throughout your treatment. Irregular timing can disrupt CB1 receptor function and reduce therapeutic benefits. Maintaining a steady dosing schedule helps optimize your…